Physician profile
Aaron Vasa
NPI 1225299290
$1,675.70
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $130 · 2021: $394 · 2022: $200 · 2023: $254 · 2024: $48.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $300.15 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $211.47 | 2021-2022 | |
| Melinta Therapeutics, LLC | $179.05 | 2019-2024 | Kimyrsa, Rezzayo, Orbactiv |
| Novartis Pharmaceuticals Corporation | $109.23 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $98.72 | 2019-2023 | Xarelto |
| Allergan, INC. | $93.82 | 2019-2020 | |
| Abbvie INC. | $65.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.56 | 2019 | |
| Mylan Specialty L.P. | $47.05 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $46.84 | 2019-2020 | |
| Advanced Respiratory, INC | $45.09 | 2019-2021 | |
| Amgen INC. | $42.66 | 2019 | |
| Merz North America, INC. | $42.05 | 2019 | |
| Genentech USA, INC. | $39.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.18 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $35.57 | 2019 | |
| Ucb, INC. | $34.71 | 2019 | |
| Acadia Pharmaceuticals INC | $25.77 | 2020-2023 | Daybue |
| Actelion Pharmaceuticals US, INC. | $24.87 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.44 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.34 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $19.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.76 | 2019 | |
| Lilly USA, LLC | $14.18 | 2019 | |
| Pfizer INC. | $14.12 | 2020 | |
| Grifols USA, LLC | $13.44 | 2019 | |
| Gilead Sciences, INC. | $12.82 | 2022 | |
| Janssen Biotech, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Vasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.